06:25 AM EDT, 08/19/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) partnered with Mesenkia Therapeutics to look for an antibody-based treatment for glioblastoma, an aggressive and treatment-resistant form of brain cancer. Under the collaboration, the Swedish biopharmaceutical company will be in charge of developing a drug candidate through the combination of its BrainTransporter technology with Mesenkia's antibody, according to a Wednesday release. Both parties expect to validate their idea in preclinical studies, the results of which will determine the path ahead.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.